Gliomas Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Glioma / [M]Glioma NOS

IndicationStatusPhase
DBCOND0032593 (Gliomas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00463203Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard TherapyTreatment
NCT00795665Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade GliomaTreatment
NCT01137604A Study in Subjects With Recurrent Malignant GliomaTreatment
NCT01967810ANG1005 in Patients With Recurrent High-Grade GliomaTreatment